Literature DB >> 17389752

Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency.

Dawn L Demeo1, Robert A Sandhaus, Alan F Barker, Mark L Brantly, Edward Eden, N Gerard McElvaney, Stephen Rennard, Esteban Burchard, James M Stocks, James K Stoller, Charlie Strange, Gerard M Turino, Edward J Campbell, Edwin K Silverman.   

Abstract

BACKGROUND: Severe alpha(1)-antitrypsin (AAT) deficiency is an autosomal recessive genetic condition associated with an increased but variable risk for chronic obstructive pulmonary disease (COPD). A study was undertaken to assess the impact of chronic bronchitis, pneumonia, asthma and sex on the development of COPD in individuals with severe AAT deficiency.
METHODS: The AAT Genetic Modifier Study is a multicentre family-based cohort study designed to study the genetic and epidemiological determinants of COPD in AAT deficiency. 378 individuals (age range 33-80 years), confirmed to be homozygous for the SERPINA1 Z mutation, were included in the analyses. The primary outcomes of interest were a quantitative outcome, forced expiratory volume in 1 s (FEV(1)) percentage predicted, and a qualitative outcome, severe airflow obstruction (FEV(1) <50% predicted).
RESULTS: In multivariate analysis of the overall cohort, cigarette smoking, sex, asthma, chronic bronchitis and pneumonia were risk factors for reduced FEV(1 )percentage predicted and severe airflow obstruction (p<0.01). Index cases had lower FEV(1) values, higher smoking histories and more reports of adult asthma, pneumonia and asthma before age 16 than non-index cases (p<0.01). Men had lower pre- and post-bronchodilator FEV(1) percentage predicted than women (p<0.0001); the lowest FEV(1) values were observed in men reporting a history of childhood asthma (26.9%). This trend for more severe obstruction in men remained when index and non-index groups were examined separately, with men representing the majority of non-index individuals with airflow obstruction (71%). Chronic bronchitis (OR 3.8, CI 1.8 to 12.0) and a physician's report of asthma (OR 4.2, CI 1.4 to 13.1) were predictors of severe airflow obstruction in multivariate analysis of non-index men but not women.
CONCLUSION: In individuals with severe AAT deficiency, sex, asthma, chronic bronchitis and pneumonia are risk factors for severe COPD, in addition to cigarette smoking. These results suggest that, in subjects severely deficient in AAT, men, individuals with symptoms of chronic bronchitis and/or a past diagnosis of asthma or pneumonia may benefit from closer monitoring and potentially earlier treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17389752      PMCID: PMC2117297          DOI: 10.1136/thx.2006.075846

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  23 in total

1.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

2.  Asthma features in severe alpha1-antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry.

Authors:  Edward Eden; Jeffrey Hammel; Farshid N Rouhani; Mark L Brantly; Alan F Barker; A Sonia Buist; Robert J Fallat; James K Stoller; Ronald G Crystal; Gerard M Turino
Journal:  Chest       Date:  2003-03       Impact factor: 9.410

3.  Alpha-1-antitrypsin genotyping with mouthwash specimens.

Authors:  R A Stockley; E J Campbell
Journal:  Eur Respir J       Date:  2001-03       Impact factor: 16.671

4.  alpha1-Antitrypsin deficiency in nonsmokers.

Authors:  L F Black; F Kueppers
Journal:  Am Rev Respir Dis       Date:  1978-03

5.  Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z.

Authors:  C Larsson
Journal:  Acta Med Scand       Date:  1978

6.  Epidemiology Standardization Project (American Thoracic Society).

Authors:  B G Ferris
Journal:  Am Rev Respir Dis       Date:  1978-12

7.  Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms.

Authors:  M L Brantly; L D Paul; B H Miller; R T Falk; M Wu; R G Crystal
Journal:  Am Rev Respir Dis       Date:  1988-08

8.  Reference spirometric values using techniques and equipment that meet ATS recommendations.

Authors:  R O Crapo; A H Morris; R M Gardner
Journal:  Am Rev Respir Dis       Date:  1981-06

9.  Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association.

Authors:  M J Tobin; P J Cook; D C Hutchison
Journal:  Br J Dis Chest       Date:  1983-01

10.  Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1998-07       Impact factor: 21.405

View more
  37 in total

Review 1.  Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease.

Authors:  Sarah K Brode; Simon C Ling; Kenneth R Chapman
Journal:  CMAJ       Date:  2012-07-03       Impact factor: 8.262

2.  Association of cigarette smoking and CRP levels with DNA methylation in α-1 antitrypsin deficiency.

Authors:  Mateusz Siedlinski; Barbara Klanderman; Robert A Sandhaus; Alan F Barker; Mark L Brantly; Edward Eden; N Gerard McElvaney; Stephen I Rennard; James M Stocks; James K Stoller; Charlie Strange; Gerard M Turino; Edward J Campbell; Dawn L Demeo
Journal:  Epigenetics       Date:  2012-07-01       Impact factor: 4.528

Review 3.  Telomerase and the Genetics of Emphysema Susceptibility. Implications for Pathogenesis Paradigms and Patient Care.

Authors:  Susan E Stanley; Samantha J Merck; Mary Armanios
Journal:  Ann Am Thorac Soc       Date:  2016-12

Review 4.  Why is Disease Penetration So Variable? Role of Genetic Modifiers of Lung Function in Alpha-1 Antitrypsin Deficiency.

Authors:  Brian D Hobbs; Michael H Cho
Journal:  Chronic Obstr Pulm Dis       Date:  2020-07

5.  Alpha 1-antitrypsin ameliorates ventilator-induced lung injury in rats by inhibiting inflammatory responses and apoptosis.

Authors:  He Zhu; Jianshuai He; Jia Liu; Xin Zhang; Fengyun Yang; Pingting Liu; Shilei Wang
Journal:  Exp Biol Med (Maywood)       Date:  2017-11-02

6.  Sex-specific differences in emphysema using a murine antisense oligonucleotide model of α-1 antitrypsin deficiency.

Authors:  Rashika Joshi; Mohit Ojha; Jana Lewis; Qiang Fan; Brett Monia; Shuling Guo; Brian M Varisco
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-04-24       Impact factor: 5.464

Review 7.  Risk of Lung Disease in PI MZ Heterozygotes. Current Status and Future Research Directions.

Authors:  Edwin K Silverman
Journal:  Ann Am Thorac Soc       Date:  2016-08

8.  Quantitative airway assessment on computed tomography in patients with alpha1-antitrypsin deficiency.

Authors:  Tsuneo Yamashiro; Shin Matsuoka; Raúl San José Estépar; Alejandro Diaz; John D Newell; Robert A Sandhaus; Patricia J Mergo; Mark L Brantly; Sadayuki Murayama; John J Reilly; Hiroto Hatabu; Edwin K Silverman; George R Washko
Journal:  COPD       Date:  2009-12       Impact factor: 2.409

Review 9.  Ecogenomics of respiratory diseases of public health significance.

Authors:  Stavros Garantziotis; David A Schwartz
Journal:  Annu Rev Public Health       Date:  2010       Impact factor: 21.981

10.  IL10 polymorphisms are associated with airflow obstruction in severe alpha1-antitrypsin deficiency.

Authors:  Dawn L Demeo; Edward J Campbell; Alan F Barker; Mark L Brantly; Edward Eden; N Gerard McElvaney; Stephen I Rennard; Robert A Sandhaus; James M Stocks; James K Stoller; Charlie Strange; Gerard Turino; Edwin K Silverman
Journal:  Am J Respir Cell Mol Biol       Date:  2007-08-09       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.